Rasagiline

Rasagiline
Clinical data
Trade names	Azilect, others
Other names	TVP-1012; TVP1012; R(+)-AGN-1135; N-Propargyl-(R)-1-aminoindan; N-Propargyl-1(R)-aminoindan; (R)-PAI
AHFS/Drugs.com	Monograph
MedlinePlus	a606017
License data	US DailyMed: Rasagiline;
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
Drug class	Monoamine oxidase inhibitor; Antiparkinsonian
ATC code	N04BD02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class C1 (Other controlled substances); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	36%
Protein binding	88–94%
Metabolism	Liver (CYP1A2)
Metabolites	• (R)-1-Aminoindan; • 3-OH-PAI; • 3-OH-AI
Elimination half-life	3 hours
Excretion	Urine: 62%; Feces: 7%
Identifiers
	IUPAC name (R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine;
CAS Number	136236-51-6 ;
PubChem CID	3052776;
IUPHAR/BPS	6641;
DrugBank	DB01367 ;
ChemSpider	2314553 ;
UNII	003N66TS6T;
KEGG	D08469 ; as salt: D02562 ;
ChEMBL	ChEMBL887 ;
PDB ligand	RAS (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID3041112 ;
ECHA InfoCard	100.301.709
Chemical and physical data
Formula	C12H13N
Molar mass	171.243 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C#CCN[C@H]2c1ccccc1CC2;
	InChI InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1 ; Key:RUOKEQAAGRXIBM-GFCCVEGCSA-N ;
	(verify)

Rasagiline, sold under the brand name Azilect among others, is a medication which is used in the treatment of Parkinson's disease. It is used as a monotherapy to treat symptoms in early Parkinson's disease or as an adjunct therapy in more advanced cases. The drug is taken by mouth.

Side effects of rasagiline include insomnia and orthostatic hypotension, among others. Rasagiline acts as an inhibitor of the enzyme monoamine oxidase (MAO) and hence is a monoamine oxidase inhibitor (MAOI). More specifically, it is a selective inhibitor of monoamine oxidase B (MAO-B). The drug is thought to work by increasing levels of the monoamine neurotransmitter dopamine in the brain. Rasagiline shows pharmacological differences from the related drug selegiline, including having no amphetamine-like metabolites, monoamine-releasing activity, or monoaminergic activity enhancer actions, which may result in clinical differences between the medications.

Rasagiline was approved for medical use in the European Union in 2005 and in the United States in 2006. Generic versions of rasagiline are available.